Anti-hIFN-γ-hIgG1
-
Cat.code:
hifng-mab1
- Documents
ABOUT
Anti-human IFN gamma - Fontolizumab biosimilar - CAS #326859-36-3
Anti-hIFN-γ-hIgG1 is a biosimilar research antibody to Fontolizumab. Fontolizumab (HuZAF) is a humanized IgG1 monoclonal antibody (mAb) that targets interferon gamma (IFN-γ). Fontolizumab blocks the interaction of IFN-γ with its receptor. Fontolizumab has been clinically tested as an immunosuppressive drug to treat inflammatory diseases, including Crohn's disease and psoriasis.
Anti-hIFN-γ-hIgG1 comprises the variable region of Fontolizumab and a human IgG1 constant region with high effector functions.
This antibody can be used with& HEK-Blue™ IFN-γ cells for screening and neutralization assays to block recombinant human IFN-γ-induced signaling (see figure).
Key features
- Each lot is functionally tested and validated.
- The complete sequence of the antibody construct was verified.
- The absence of endotoxins is determined using the EndotoxDetect™ assay.
All products are for internal research use only, and not for human or veterinary use.
SPECIFICATIONS
Specifications
Human IFN-γ
Human
Sodium phosphate buffer, glycine, saccharose, stabilizing agents
Negative (tested using EndotoxDetect™ assay)
Neutralization assay
Each lot is functionally tested and validated.
CONTENTS
Contents
-
Product:Anti-hIFN-γ-hIgG1
-
Cat code:hifng-mab1
-
Quantity:100 µg
Shipping & Storage
- Shipping method: Room temperature
- -20°C
- Avoid repeated freeze-thaw cycles
Storage:
Caution:
Details
Fontolizumab background
Fontolizumab (aka HuZAF™) is a therapeutic, humanized monoclonal antibody (mAb) that targets the human interferon-gamma (IFN-γ) cytokine [1, 2]. By binding to IFN-γ, Fontolizumab prevents it from interacting with its receptor (IFN-γR) on the surface of immune cells, thus inhibiting downstream inflammatory response. Fontolizumab was used as an immunosuppressive drug to treat inflammatory diseases, including Crohn's disease and psoriasis. While the mode of action was promising, clinical trials did not demonstrate sufficient clinical benefit [3, 4].
References:
1. Hommes D.W., et al., 2006. Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut, 55(8):1131-1137.
2. Reinisch W et al., 2006. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease. Gut, 55(8):1138-1144.
3. Reinisch W et al., 2009. Fontolizumab in moderate to severe Crohn's disease: A phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Infl Bowel Dis., 16(2):233-242.
4. Harden J.L., et al., 2015. Humanized anti-IFNg (HuZAF) in the treatment of psoriasis. J. Aller Clin Immunol. 135(2):553.
DOCUMENTS
Documents
Technical Data Sheet
Validation Data Sheet
Safety Data Sheet
Certificate of analysis
Need a CoA ?
